The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.
Dynacure, the France-based muscular disease treatment developer spun out of Institute of Genetic and Molecular and Cellular Biology (IGBMC), has set the range for an initial public offering that could raise up to $107m.
The company plans to offer 6.3 million American depository shares (ADSs), each representing one ordinary share, at a price range of $15 to $17 on the Nasdaq Global Market. The upper end of the range would imply a market valuation of approximately $334m.
Founded…
